Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 4/20 | 0.48 |
| ▸ | GSK3B | P49841 | 4/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | ULK1 | O75385 | 4/20 | 0.46 |
| ▸ | ULK2 | Q8IYT8 | 2/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.45 |
| ▸ | FLT3 | P36888 | 5/20 | 0.44 |
| ▸ | KIT | P10721 | 4/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11915897 | 1.00 | GSK3A (0.48) | GSK3AGSK3BAURKAULK1ULK2 | |
| SCHEMBL22515365 | 0.95 | AURKA (0.44) | GSK3AGSK3BAURKAULK1ULK2 | |
| SCHEMBL19288513 | 0.88 | ULK1 (0.43) | GSK3AGSK3BAURKAULK1ULK2 | |
| SCHEMBL11916313 | 0.86 | PTK2 (0.47) | AURKAPTK2FLT3KITCHEK1 | |
| SCHEMBL15221834 | 0.86 | GSK3A (0.43) | GSK3AGSK3BAURKAULK1ULK2 | |
| SCHEMBL15498462 | 0.83 | ULK1 (0.50) | AURKAULK1ULK2PTK2FLT3 | |
| SCHEMBL19288510 | 0.81 | JAK3 (0.46) | AURKAULK1ULK2PTK2FLT3 | |
| SCHEMBL15217776 | 0.81 | PTK2 (0.44) | AURKAULK1ULK2PTK2FLT3 | |
| SCHEMBL11916655 | 0.79 | GSK3A (0.67) | GSK3AGSK3BAURKAULK1ULK2 | |
| SCHEMBL19313030 | 0.79 | GABBR2 (0.40) | GSK3AGSK3BULK1FLT3KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | PHKA1, PIK3CA, PHKA2 | GSK3A 165/4885GSK3B 154/4885AURKA 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.